Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019
Shots:
- The P-III IMbrave150 study involve assessing of Tecentriq (1200mg- IV) + Avastin (IV- 15 mg/kg) vs Sorafenib (PO- 400mg- bid) in 501 patients in a ratio 2:1 with unresectable HCC prior not treated with systemic therapies
- The P-III IMbrave 150 study results: 42% reduction in risk of death- 41% reduction in risk of disease worsening; mOS (not reached vs 13.2mos.); mPFS (6.8 mos. vs 4.3mos.) measured as per IRF RECIST v1.1.; median follow-up 8.6 months; AEs (57% vs 55%)- presented at ESMO Congress 2019
- Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1receptors. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity- by inhibiting VEGF related immunosuppression
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com